Normal view

Received — 24 December 2024 ⏭ Favourites

Nature - Issue - nature.com science feeds
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers Daniel Zingg · Jinhyuk Bhin · Julia Yemelyanenko · Sjors M. Kas · Frank Rolfs · Catrin Lutz · Jessica K. Lee · Sjoerd Klarenbeek · Ian M. Silverman · Stefano Annunziato · Chang S. Chan · Sander R. Piersma · Timo Eijkman · Madelon Badoux · Ewa Gogola · Bjørn Siteur · Ju
Nature, Published online: 10 August 2022; doi:10.1038/s41586-022-05066-5Truncation of exon 18 of FGFR2 (FGFR2ΔE18) is a potent driver mutation in mice and humans, and FGFR-targeted therapy should be considered for patients with cancer expressing stable FGFR2ΔE18 variants.
10 August 2022 at 08:00

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Nature - Issue - nature.com science feeds

By: Daniel Zingg · Jinhyuk Bhin · Julia Yemelyanenko · Sjors M. Kas · Frank Rolfs · Catrin Lutz · Jessica K. Lee · Sjoerd Klarenbeek · Ian M. Silverman · Stefano Annunziato · Chang S. Chan · Sander R. Piersma · Timo Eijkman · Madelon Badoux · Ewa Gogola · Bjørn Siteur · Ju

10 August 2022 at 08:00

Nature, Published online: 10 August 2022; doi:10.1038/s41586-022-05066-5

Truncation of exon 18 of FGFR2 (FGFR2ΔE18) is a potent driver mutation in mice and humans, and FGFR-targeted therapy should be considered for patients with cancer expressing stable FGFR2ΔE18 variants.